Seat­tle biotech found­ed by for­mer Seagen lead­ers nabs $112M for three clin­i­cal-stage AD­Cs

Pro­found­Bio will use a larg­er-than-planned Se­ries B to fi­nance three clin­i­cal-stage an­ti­body-drug con­ju­gates, in­clud­ing tak­ing its lead com­pound in­to a piv­otal study and help­ing ad­vance mul­ti­ple Phase I-stage drugs.

The Seat­tle biotech’s $112 mil­lion round, dis­closed Tues­day morn­ing, will back what has be­come one of the hottest ar­eas in on­col­o­gy on the promise of de­liv­er­ing tar­get­ed, pow­er­ful and po­ten­tial­ly safer can­cer-killing drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER